Your browser is no longer supported. Please, upgrade your browser.
Settings
PRTK Paratek Pharmaceuticals, Inc. daily Stock Chart
PRTK [NASD]
Paratek Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-3.76 Insider Own4.30% Shs Outstand34.29M Perf Week4.35%
Market Cap131.67M Forward P/E- EPS next Y-3.42 Insider Trans-1.77% Shs Float31.36M Perf Month-9.43%
Income-120.20M PEG- EPS next Q-1.15 Inst Own79.20% Short Float34.40% Perf Quarter-38.46%
Sales18.70M P/S7.04 EPS this Y-7.40% Inst Trans2.75% Short Ratio34.97 Perf Half Y-33.91%
Book/sh0.50 P/B7.68 EPS next Y22.10% ROA-39.50% Target Price21.75 Perf Year-64.11%
Cash/sh7.52 P/C0.51 EPS next 5Y- ROE-232.60% 52W Range3.40 - 12.30 Perf YTD-25.15%
Dividend- P/FCF- EPS past 5Y54.60% ROI-37.80% 52W High-68.54% Beta1.81
Dividend %- Quick Ratio14.00 Sales past 5Y104.60% Gross Margin98.90% 52W Low13.82% ATR0.28
Employees101 Current Ratio14.10 Sales Q/Q15880.00% Oper. Margin- RSI (14)44.14 Volatility5.70% 7.15%
OptionableYes Debt/Eq0.00 EPS Q/Q-21.30% Profit Margin- Rel Volume1.93 Prev Close3.84
ShortableYes LT Debt/Eq14.33 EarningsMay 08 AMC Payout- Avg Volume308.49K Price3.87
Recom1.40 SMA202.10% SMA50-18.40% SMA200-42.13% Volume188,007 Change0.78%
Jan-02-19Initiated Canaccord Genuity Buy $14
Nov-23-18Reiterated H.C. Wainwright Buy $55 → $22
Aug-27-18Initiated BofA/Merrill Neutral $13
Mar-02-18Downgrade Raymond James Strong Buy → Outperform
Oct-24-17Initiated Guggenheim Buy $44
Jul-18-17Reiterated H.C. Wainwright Buy $36 → $43
May-19-17Initiated Raymond James Strong Buy
Apr-11-17Reiterated H.C. Wainwright Buy $33 → $36
Apr-04-17Reiterated Wedbush Outperform $30 → $34
Apr-04-17Initiated Wedbush Outperform $30
Oct-27-16Resumed Leerink Partners Outperform $23
Jun-17-16Reiterated H.C. Wainwright Buy $31 → $34
May-13-16Initiated Robert W. Baird Outperform $30
Mar-30-16Resumed Cantor Fitzgerald Buy $27
Feb-29-16Initiated H.C. Wainwright Buy $32
Jul-22-15Initiated Gabelli & Co Buy $34
May-15-15Initiated Leerink Partners Outperform
May-12-15Initiated Cantor Fitzgerald Buy $35
May-11-15Initiated Guggenheim Buy $38
Jun-20-19 11:13AM  Antimicrobials Working Group Highlights Member Company Participation at ASM Microbe 2019 PR Newswire
Jun-07-19 09:27AM  Antimicrobials Working Group Commends Senator Isakson and Senator Casey for Introducing Legislation to Improve Access to Innovative Therapies to Fight Drug-Resistant Infections PR Newswire
May-30-19 02:27PM  Penny Stocks to Buy Using Technical Analysis for June 2019 Investopedia -5.34%
May-20-19 07:15AM  Edited Transcript of PRTK earnings conference call or presentation 8-May-19 8:30pm GMT Thomson Reuters StreetEvents -6.81%
May-08-19 05:25PM  Paratek Pharmaceuticals (PRTK) Reports Q1 Loss, Tops Revenue Estimates Zacks
04:25PM  Paratek: 1Q Earnings Snapshot Associated Press
04:05PM  Parateks NUZYRA (omadacycline) Generates Net Sales of $1.3 Million in the First Eight Weeks on the U.S. Market GlobeNewswire
May-01-19 10:32AM  Analysts Estimate Paratek Pharmaceuticals (PRTK) to Report a Decline in Earnings: What to Look Out for Zacks
Apr-30-19 04:05PM  Paratek Pharmaceuticals to Report First Quarter 2019 Financial Results on May 8, 2019 GlobeNewswire
Apr-20-19 09:27AM  Should You Be Pleased About The CEO Pay At Paratek Pharmaceuticals, Inc.'s (NASDAQ:PRTK) Simply Wall St.
Apr-15-19 04:30PM  Paratek Pharmaceuticals Broadens Clinical Profile of NUZYRA (Omadacycline) with New ECCMID 2019 Data Presentations GlobeNewswire -6.33%
Apr-12-19 10:08AM  Antimicrobials Working Group Highlights Member Company Participation at the 29th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) PR Newswire
Apr-04-19 08:30AM  Paratek Pharmaceuticals Presenting New Data from NUZYRA (Omadacycline) Development Program at ECCMID 2019 GlobeNewswire
Apr-01-19 09:05AM  Paratek Pharmaceuticals Receives American Chemical Society 2019 Heroes of Chemistry Award GlobeNewswire +5.41%
08:10AM  Market Trends Toward New Normal in Verizon Communications, Digital Turbine, Vericel, Capstead Mortgage, Paratek Pharmaceuticals, and CryoPort Emerging Consolidated Expectations, Analyst Ratings GlobeNewswire
Mar-28-19 08:00AM  Paratek Pharmaceuticals to Present at the 2019 H.C Wainwright Global Life Sciences Conference GlobeNewswire
Mar-20-19 01:35PM  Seth Klarman's Small Caps: Worth a Look? GuruFocus.com
Mar-18-19 08:00AM  Paratek Pharmaceuticals Announces Management Change GlobeNewswire
Mar-07-19 12:47PM  What Should Investors Know About Paratek Pharmaceuticals, Inc.s (NASDAQ:PRTK) Future? Simply Wall St.
Mar-05-19 07:49PM  Edited Transcript of PRTK earnings conference call or presentation 27-Feb-19 9:30pm GMT Thomson Reuters StreetEvents
Mar-01-19 04:30PM  Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire
08:00AM  Paratek Pharmaceuticals to Present at the Cowen and Company 39th Annual Health Care Conference GlobeNewswire
Feb-27-19 09:08PM  Paratek Pharmaceuticals Inc (PRTK) Q4 2018 Earnings Conference Call Transcript Motley Fool
04:01PM  Paratek Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results GlobeNewswire
Feb-20-19 10:31AM  Will Paratek Pharmaceuticals (PRTK) Report Negative Earnings Next Week? What You Should Know Zacks
Feb-14-19 04:05PM  Paratek Pharmaceuticals to Present at the 8th Annual SVB Leerink Global Healthcare Conference GlobeNewswire
Feb-13-19 04:05PM  Paratek Pharmaceuticals to Report Fourth Quarter and Full Year 2018 Financial Results on February 27, 2019 GlobeNewswire
Feb-06-19 05:05PM  New England Journal of Medicine Publishes Results from Pivotal Phase 3 Studies of Parateks NUZYRA (Omadacycline) For Pneumonia and Skin Infections GlobeNewswire
08:23AM  The Daily Biotech Pulse: Paratek Launches Antibiotic In US, Eli Lilly Earnings, Catabasis Offering Benzinga
Feb-05-19 04:05PM  Paratek Pharmaceuticals Launches NUZYRA (Omadacycline) in the United States GlobeNewswire
Feb-01-19 04:01PM  Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire
Jan-18-19 11:09AM  What You Must Know About Paratek Pharmaceuticals, Inc.s (NASDAQ:PRTK) Beta Value Simply Wall St.
Jan-17-19 10:00AM  Antimicrobials Working Group Announces Updates to Leadership Team PR Newswire
Jan-02-19 04:01PM  Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire +8.58%
Dec-16-18 02:47AM  Arbiter Partners Capital Managements Returns, AUM and Holdings Insider Monkey
Dec-08-18 09:58PM  Hedge Funds Are Selling Paratek Pharmaceuticals Inc (PRTK) Insider Monkey
Dec-06-18 07:30AM  Analysis: Positioning to Benefit within Paratek Pharmaceuticals, Chesapeake Utilities, Eros International, Sunoco LP, Delek Logistics Partners, and Johnson Controls International plc Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire
Dec-03-18 04:01PM  Paratek Pharmaceuticals Files Two Patent Term Extensions in the United States; Expects NUZYRA Patent Protection Exclusivity Until at Least October 2030 GlobeNewswire
Nov-27-18 08:00AM  Paratek Pharmaceuticals Doses First Patient in Phase 2 Clinical Trial of Omadacycline in Acute Pyelonephritis, a Common Subset of Complicated Urinary Tract Infections GlobeNewswire
Nov-18-18 11:31PM  Edited Transcript of PRTK earnings conference call or presentation 6-Nov-18 9:30pm GMT Thomson Reuters StreetEvents
Nov-15-18 12:28PM  Do Institutions Own Paratek Pharmaceuticals Inc (NASDAQ:PRTK) Shares? Simply Wall St.
Nov-06-18 05:50PM  Paratek Pharmaceuticals (PRTK) Reports Q3 Loss, Misses Revenue Estimates Zacks
04:48PM  Paratek: 3Q Earnings Snapshot Associated Press
04:02PM  Paratek Pharmaceuticals Reports Third Quarter 2018 Financial Results GlobeNewswire
Nov-01-18 04:05PM  Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire
Oct-26-18 04:05PM  Paratek Pharmaceuticals to Report Third Quarter 2018 Financial Results on November 6, 2018 GlobeNewswire
08:45AM  Investor Expectations to Drive Momentum within Paratek Pharmaceuticals, Dell Technologies, Dover, Black Hills, Kinder Morgan, and Novo Nordisk A/S Discovering Underlying Factors of Influence GlobeNewswire
Oct-25-18 01:12PM  War against the superbugs: Mass. biotechs step up to fight antibiotic resistance American City Business Journals
Oct-22-18 01:56PM  5 Low-Priced Biotech Stocks to Take Advantage of the Market Rout InvestorPlace
Oct-05-18 10:55AM  Major Action in Biotech and This is The Next Winner ACCESSWIRE
Oct-04-18 04:30PM  Why Barnes & Noble, Paratek Pharmaceuticals, and Hortonworks Jumped Today Motley Fool +12.85%
04:01PM  Paratek Announces Acceptance of European Marketing Authorization Application for Oral and Intravenous Omadacycline GlobeNewswire
08:40AM  Paratek Pharmaceuticals (PRTK) in Focus: Stock Moves 8.7% Higher Zacks
Oct-03-18 04:05PM  Paratek Pharmaceuticals, Inc. to Host Investor Day on October 23, 2018 GlobeNewswire +8.66%
12:45PM  FDA Approves Paratek's Bacterial Pneumonia, Skin Infection Treatment Benzinga
12:43PM  Paratek gets second FDA approval in past 24 hours American City Business Journals
10:37AM  Paratek (PRTK) Gets FDA Approval for Nuzyra and Seysara Zacks
08:53AM  Implied Volatility Surging for Paratek Pharmaceuticals (PRTK) Stock Options Zacks
08:00AM  Today's Research Reports on Trending Tickers: Paratek Pharmaceuticals and Trevena ACCESSWIRE
Oct-02-18 07:18PM  US regulators OK updated version of decades-old antibiotic Associated Press -5.04%
08:45AM  FDA Approves SEYSARA (Sarecycline) for the Treatment of Moderate to Severe Acne GlobeNewswire
Oct-01-18 04:01PM  Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire
Sep-26-18 07:40AM  Factors of Influence in 2018, Key Indicators and Opportunity within Sina, Paratek Pharmaceuticals, Honda Motor Co., Prospect Capital, G1 THERAPEUTICS, and Gaming and Leisure Properties New Research Emphasizes Economic Growth GlobeNewswire
Sep-25-18 08:00AM  Paratek Pharmaceuticals Presenting New Omadacycline Data at IDWeek 2018 GlobeNewswire
Sep-04-18 04:30PM  Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire
Aug-30-18 06:21AM  Mass. antibiotics developers say the field is getting slowly better American City Business Journals
Aug-29-18 04:05PM  Paratek Pharmaceuticals to Present at Baird's 2018 Global Healthcare Conference GlobeNewswire
Aug-08-18 04:07PM  FDA panel recommends approval of Paratek's antibiotic American City Business Journals
02:20PM  FDA Advisory Committee Recommends Approval of Parateks Omadacycline GlobeNewswire
02:03PM  U.S. FDA panel backs approval of Paratek's antibiotic Reuters
01:18PM  U.S. FDA panel backs approval of Paratek's antibiotic Reuters
07:05AM  Paratek Pharmaceuticals Stock Trading Halted Today; FDA Advisory Committee to Review Omadacycline New Drug Applications for the Treatment of Community-Acquired Bacterial Pneumonia and Acute Bacterial Skin and Skin Structure Infections GlobeNewswire
Aug-06-18 08:58AM  Paratek antibiotic not inferior to current treatments-FDA staff Reuters +11.73%
05:19AM  Edited Transcript of PRTK earnings conference call or presentation 2-Aug-18 8:30pm GMT Thomson Reuters StreetEvents
Aug-02-18 07:05PM  Paratek Pharmaceuticals (PRTK) Reports Q2 Loss, Misses Revenue Estimates Zacks
05:58PM  Paratek: 2Q Earnings Snapshot Associated Press
04:01PM  Paratek Pharmaceuticals Reports Second Quarter 2018 Financial Results GlobeNewswire
02:30PM  Paratek Pharmaceuticals Inc to Host Earnings Call ACCESSWIRE
Jul-23-18 07:30AM  Paratek Pharmaceuticals to Report Second Quarter 2018 Financial Results on August 2, 2018 GlobeNewswire
Jul-18-18 07:45AM  Initiating Free Research Reports on Pieris Pharma and Three Other Biotech Equities ACCESSWIRE
Jun-21-18 10:35AM  Paratek's Antibiotic Candidate Gets FDA Committee Date Zacks
Jun-20-18 09:05AM  Paratek Announces FDA Advisory Committee Date for Omadacycline GlobeNewswire
Jun-07-18 04:05PM  Paratek Demonstrates Breadth of Omadacycline Clinical and Microbiological Data at ASM Microbe 2018 GlobeNewswire
Jun-06-18 10:08AM  Antimicrobials Working Group Highlights Member Company Participation at ASM Microbe 2018 PR Newswire
Jun-01-18 04:30PM  Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire
May-31-18 07:35AM  Market Trends Toward New Normal in Gaming and Leisure Properties, SMART SAND INC, ARMOUR Residential REIT, Aegon NV, Paratek Pharmaceuticals, and Clearside Biomedical Emerging Consolidated Expectations, Analyst Ratings GlobeNewswire
May-22-18 04:01PM  Paratek Presents New Analysis Highlighting Efficacy of Omadacycline in Treating Community-Acquired Bacterial Pneumonia by Measures of Disease Severity GlobeNewswire
May-21-18 12:35PM  What Investors Should Know About Paratek Pharmaceuticals Incs (NASDAQ:PRTK) Financial Strength Simply Wall St.
May-16-18 03:42PM  Edited Transcript of PRTK earnings conference call or presentation 9-May-18 12:30pm GMT Thomson Reuters StreetEvents
May-09-18 08:01AM  Paratek: 1Q Earnings Snapshot Associated Press
07:30AM  Paratek Pharmaceuticals Reports First Quarter 2018 Financial Results GlobeNewswire
May-08-18 05:45PM  5 Biotech Stocks Set to Beat Estimates This Earnings Season Zacks
May-01-18 04:01PM  Paratek Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire
Apr-25-18 05:03PM  Paratek Pharmaceuticals to Report First Quarter 2018 Financial Results on May 9, 2018 GlobeNewswire +7.77%
Apr-23-18 07:30AM  Paratek Pharmaceuticals Presents New Microbiology Efficacy Data of Oral-only Omadacycline Against the Most Common Pathogens Associated with Skin Infections GlobeNewswire
07:30AM  Paratek Pharmaceuticals Presents Data Supporting Potential Approval of Omadacycline for Treatment of Community-Acquired Bacterial Pneumonia Based on the EMA Guidelines at ECCMID GlobeNewswire
Apr-20-18 10:17AM  Antimicrobials Working Group Highlights Member Company Participation at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) PR Newswire
Apr-19-18 12:45PM  Here's Why Paratek Pharmaceuticals Dropped as Much as 16.6% Today Motley Fool -15.28%
08:45AM  Paratek Pharmaceuticals, Inc. Prices $140 Million of Convertible Senior Subordinated Notes due 2024 GlobeNewswire
Apr-18-18 04:01PM  Paratek Pharmaceuticals, Inc. Announces Proposed Private Offering of $125 Million of Convertible Senior Subordinated Notes due 2024 GlobeNewswire
Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics based upon biology and tetracycline chemistry in the United States. Its lead product candidates include omadacycline, an intravenous and oral antibiotic for use as a monotherapy antibiotic for acute bacterial skin and skin structure infections, community-acquired bacterial pneumonia, urinary tract infections, and other community-acquired bacterial infections; and Sarecycline, a tetracycline-derived compound designed for use in the treatment of acne and rosacea. The company has license and collaboration agreements with Zai Lab (Shanghai) Co., Ltd. and Allergan plc; license agreement with Tufts University to develop and commercialize products for the treatment or prevention of bacterial or microbial diseases, or medical conditions; and cooperative research and development agreement with the U.S. Army Medical Research Institute of Infectious Diseases to study omadacycline against pathogenic agents causing infectious diseases. Paratek Pharmaceuticals, Inc. was founded in 1996 and is headquartered in Boston, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Dietz Thomas JohnDirectorFeb 15Sale7.143,00021,4204,500Feb 20 04:57 PM
Radie Robert SDirectorFeb 15Sale7.143,75026,7756,750Feb 20 04:52 PM
Stein JeffreyDirectorFeb 15Sale7.143,37524,09810,125Feb 20 04:45 PM
Woodrow AdamVP & Chief Commercial OfficerFeb 05Sale6.773,33122,551144,694Feb 07 04:49 PM
Pagan Douglas W.Chief Financial OfficerFeb 05Sale6.772,49516,891134,057Feb 07 04:44 PM
Haskel William M.Sr. VP, Sec. & General CounselFeb 05Sale6.771,3319,011112,220Feb 07 04:38 PM
Dietz Thomas JohnDirectorDec 21Sale5.019,33046,7437,500Dec 26 04:05 PM
Haskel William M.Sr. VP, Sec. & General CounselDec 13Sale6.251,0006,25098,551Dec 14 05:39 PM
Loh EvanPresident, COO and CMODec 13Sale6.276,00037,620277,700Dec 14 05:35 PM
BIGHAM MICHAELChairman and CEODec 12Sale6.768,40056,784256,467Dec 14 05:45 PM
Pagan Douglas W.Chief Financial OfficerDec 12Sale6.762,91819,726120,302Dec 14 05:42 PM
Haskel William M.Sr. VP, Sec. & General CounselDec 12Sale6.763,13221,17299,551Dec 14 05:39 PM
Loh EvanPresident, COO and CMODec 12Sale6.765,52537,349283,700Dec 14 05:35 PM
Woodrow AdamVP & Chief Commercial OfficerDec 12Sale6.763,73325,235131,775Dec 14 05:32 PM
BIGHAM MICHAELChairman and CEOOct 15Sale8.966,30056,448264,867Oct 16 08:02 PM
Pagan Douglas W.Chief Financial OfficerOct 15Sale8.962,78424,945123,220Oct 16 07:58 PM
Haskel William M.Sr. VP, Sec. & General CounselOct 15Sale8.962,23119,990102,683Oct 16 07:55 PM
Loh EvanPresident, COO and CMOOct 15Sale8.965,20046,592289,225Oct 16 07:51 PM
Woodrow AdamVP & Chief Commercial OfficerOct 15Sale8.962,65923,825135,508Oct 16 07:48 PM
Loh EvanPresident, COO and CMOOct 03Sale9.828,86187,015281,425Oct 04 08:41 PM
Haskel William M.Sr. VP, Sec. & General CounselOct 03Sale9.825,86057,54598,914Oct 04 09:10 PM
BIGHAM MICHAELChairman and CEOOct 03Sale9.8216,313160,194257,167Oct 04 09:06 PM
Woodrow AdamVP & Chief Commercial OfficerOct 03Sale9.828,75085,925131,667Oct 04 09:03 PM
Pagan Douglas W.Chief Financial OfficerOct 03Sale9.827,57974,426119,504Oct 04 08:59 PM
Loh EvanPresident, COO and CMOJul 02Sale9.9712,000119,640202,786Jul 05 06:46 PM
Haskel William M.Sr. VP, Sec. & General CounselJul 02Sale9.977,32373,01062,274Jul 05 06:24 PM
BIGHAM MICHAELChairman and CEOJul 02Sale9.9722,500224,325177,230Jul 05 06:21 PM